SAbR as an Alternative Boost Modality for Cervical Cancer: A Cautionary Exercise

Kamrava, Mitchell; Chino, Junzo; Beriwal, Sushil

doi:10.1016/j.ijrobp.2019.11.026

Cited by 4 publications

(3 citation statements)

References 13 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The declining use of brachytherapy and limited trainee experience with this technique is concerning as brachytherapy is a key component of curative treatment for several different malignancies (6). Although brachytherapy was initially developed because of limitations of external-beam treatment delivery, recent studies have demonstrated that even newer technologies, such as stereotactic body radiation therapy, result in decreased cure rates and high rates of toxicity compared with brachytherapy for patients with cervical cancer (15,16). Similarly, despite evidence showing efficacy in the treatment of low-and intermediate-risk prostate cancer, there has also been a decreased utilization of prostate brachytherapy, despite long-term clinical outcomes, single-fraction regimens, and data demonstrating the value of such approaches (9,17).…”

Section: Discussionmentioning

confidence: 99%

#ThisIsBrachytherapy: Increasing awareness of brachytherapy

Kahn

Campbell

Albert³

et al. 2021

Brachytherapy

View full text Add to dashboard Cite

The use of brachytherapy continues to be a vital application of radiation oncology for various cancers. Despite this, there has been a decrease in the utilization of brachytherapy in many cancers. Social media in medicine facilitates engagement and advocacy. We launched a social media campaign to bring awareness of brachytherapy throughout the world with #ThisIsBrachytherapy hashtag on July 17, 2019. METHODS AND MATERIALS: #ThisIsBrachytherapy hashtag was registered with Symplur Healthcare Hashtag Project. We collected total tweet counts, retweet counts, impression counts, geolocation, top 10 influencers, associated hashtags, associated words, and word sentiment score. RESULTS: The campaign launched on July 17, 2019, had a total of 145 tweets on that day with 213,416 impressions. Twenty-seven accounts (45%) were identified as physicians. Top countries which tweeted, among those with information available, included the United States, United Kingdom, and Australia. Since July 17, 2019, there has been an increase in tweets using #ThisIs-Brachytherapy, with 1990 total tweets with 1,999,248 impressions. Fifty-four percent (1030) of the tweets contained photos and 319 contained links. This was from 462 unique users. Word sentiment was overwhelmingly positive. Associated hashtags with #ThisIsBrachytherapy included most commonly #radonc, #brachytherapy, #brachy, #prostatecancer, and #pcsm. CONCLUSIONS: The #ThisIsBrachytherapy inaugural campaign was successful and has continued to grow throughout the months after the initiation. By continuing to advocate for brachytherapy through the social media campaign #ThisIsBrachytherapy, we can empower radiation oncologists, especially trainees, and patients to address underutilization.

show abstract

Section: Discussionmentioning

confidence: 99%

#ThisIsBrachytherapy: Increasing awareness of brachytherapy

Kahn

Campbell

Albert³

et al. 2021

Brachytherapy

View full text Add to dashboard Cite

show abstract

“…Initial localized treatment of cervical cancers generally includes the use of brachytherapy boost after external beam. The role of SBRT in lieu of brachytherapy for those who have relative contraindications or lack of access to the procedure is an important topic of investigation 3…”

Section: Sbrt In the Management Of Primary And Locally Recurrent Diseasementioning

confidence: 99%

“…The role of SBRT in lieu of brachytherapy for those who have relative contraindications or lack of access to the procedure is an important topic of investigation. 3 There have been few studies that have reviewed outcomes of patients who received SBRT boost in lieu of brachytherapy boost for a primary gynecologic malignancy (Table 1). A retrospective study including 25 patients with newly diagnosed cervical cancer treated with external beam radiotherapy followed by SBRT boost reported a 3-year local control rate of 80.9% with 20% of patients experiencing grade 3 toxicity including hematuria and hematochezia.…”

Section: Sbrt In the Management Of Primary And Locally Recurrent Diseasementioning

confidence: 99%

Role of stereotactic body radiotherapy in gynecologic radiation oncology

Shenker

Stephens

Davidson³

et al. 2022

Int J Gynecol Cancer

View full text Add to dashboard Cite

Stereotactic body radiotherapy (SBRT, also referred to as stereotactic ablative radiotherapy (SABR)) has been used in the treatment of primary and metastatic solid tumors, and increasingly so in gynecologic oncology. This review article aims to summarize the current literature describing the utility of SBRT in the primary, recurrent, and limited metastatic settings for gynecologic malignancies. The use of SBRT in both retrospective and prospective reports has been associated with adequate control of the treated site, particularly in the setting of oligometastatic disease. It is not, however, recommended as an alternative to brachytherapy for intact disease unless all efforts to use brachytherapy are exhausted. While phase I and II trials have established the relative safety and potential toxicities of SBRT, there remains a dearth of phase III randomized evidence, including the use of immunotherapy, in order to better establish the role of this technique as a method of improving more global outcomes for our patients with gynecologic cancers.

show abstract